ENTITY
Transcenta

Transcenta (6628 HK)

17
Analysis
Health Care • China
Transcenta is a clinical-stage biopharmaceutical company with integrated capabilities in the discovery, research, development, manufacturing, and business development of biopharmaceuticals. The company develops therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders, and also provides contract development and manufacturing organization (CDMO) services. Transcenta is headquartered in Suzhou, China, and was founded in 2010.
more
Exchange Announcement • 12 Oct 2026 08:03

Voluntary Announcement-Business Update On The Grant Of China Invention Patents Related To Osemitamab (Tst001) And Its Companion Diagnostic Antibody

Exchange Announcement • 30 Sep 2026 20:44

Cancellation And Grant Of Award Pursuant To The Share Incentive Scheme

Exchange Announcement • 15 Sep 2026 16:36

Notification Letter And Request Form To Non-Registered Holders

Exchange Announcement • 15 Sep 2026 16:34

Notification Letter And Reply Form To Registered Holders

Exchange Announcement • 15 Sep 2026 16:30

2026 Interim Report

x